Study of Icotinib Hydrochloride in Treating Patients With Recurrent or Metastatic Esophageal Cancer After Failure of Conventional Chemotherapy

Inclusion Criteria: * Patients have provided a signed Informed Consent Form * Age: 18-75 years old * Histologically confirmed diagnosis of esophageal squamous cell carcinoma * Patients have Received and progressed on 1 line of prior Fluoropyrimidine, platinum or taxane based palliative chemotherapy * Measurable disease in at least 1 diameter by CT scan or MRI as per RECIST 1.1 criteria * Life expectancy ≥ 3 months * Karnofsky score ≥70 * Patient has adequate bone marrow and organ function * Absolute Neutrophil Count (ANC) ≥ 1.5 x 109/L * Platelets ≥ 75 x 109/L * Hemoglobin ≥ 9.0 g/dL * Patient has adequate liver function * AST and ALT not more than 2.5 times ULN (not more than 5.0 times ULN if there is liver metastasis) * Serum bilirubin ≤ 2 x ULN * Creatinine ≤ 1.5 times ULN * No malabsorption or other gastrointestinal disorders affecting drug absorption. * No serious complications such as active gastrointestinal hemorrhage, perforation, jaundice, gastrointestinal obstruction, non cancerous fever \> 38 ℃. * Expect good compliance Exclusion Criteria: * Patient has received previous treatment with EGFR inhibitors * Patient is currently receiving Phenytoin, rifampin, barbiturates, C Masi Bing * Known severe hypersensitivity to Icotinib or any of the excipients of this product * CNS metastases without radiotherapy and/or surgery * Patients with treated CNS metastases may participate in this trial,except for those who must receive hormone therapy and those whose prior hormone therapy for CNS metastases is less than 4 weeks * Evidence of clinically active Interstitial Lung Diseases * Severe systemic disease out of control such as unstable or uncompensated respiratory,cardiac,liver,renal diseases * Patient has a concurrent malignancy or has a malignancy within 5 years of study enrollment, (with the exception of nonmelanoma skin cancer or cervical carcinoma in situ * psychiatric illness that would prevent the patient from giving informed consent * Patient is concurrently using other approved or investigational antineoplastic agent * Pregnant or lactating women